Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XPNPEP1 | Q9NQW7 | 3/20 | 0.51 |
| ▸ | CAPN1 | P07384 | 6/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | PEPD | P12955 | 5/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 3/20 | 0.41 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30906750 | 0.89 | CAPN1 (0.56) | XPNPEP1CAPN1CTSBPEPDSTAT3 | |
| SCHEMBL30906745 | 0.87 | XPNPEP1 (0.51) | XPNPEP1CAPN1CTSBPEPDKMT2A | |
| SCHEMBL30906729 | 0.86 | XPNPEP1 (0.50) | XPNPEP1CAPN1CTSBPEPDKMT2A | |
| SCHEMBL30906736 | 0.86 | XPNPEP1 (0.50) | XPNPEP1CAPN1CTSBPEPDKMT2A | |
| SCHEMBL30906707 | 0.85 | XPNPEP1 (0.49) | XPNPEP1CAPN1CTSBPEPDKMT2A | |
| SCHEMBL30906746 | 0.83 | ANPEP (0.50) | XPNPEP1CAPN1CTSBPEPD | |
| SCHEMBL31061617 | 0.83 | XPNPEP1 (0.54) | XPNPEP1CAPN1CTSBPEPDXIAP | |
| SCHEMBL30906724 | 0.83 | XPNPEP1 (0.47) | XPNPEP1CAPN1CTSBPEPDKMT2A | |
| SCHEMBL30906741 | 0.81 | XPNPEP1 (0.50) | XPNPEP1CAPN1CTSBPEPDSTAT3 | |
| SCHEMBL30906713 | 0.81 | XPNPEP1 (0.56) | XPNPEP1CAPN1CTSBPEPDXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368624-A1 | M24B AMINOPEPTIDASE INHIBITORS FOR CARD8 INFLAMMASOME ACTIVATION | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2025-12-04 | — | — | US | disclosed |
| WO-2024077087-A2 | M24B AMINOPEPTIDASE INHIBITORS FOR CARDS INFLAMMASOME ACTIVATION | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2024-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368624-A1 | M24B AMINOPEPTIDASE INHIBITORS FOR CARD8 INFLAMMASOME ACTIVATION | PYCARD, NLRP3, CARD19 | XPNPEP1 41/4885CAPN1 934/4885CTSB 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.